Previous close | 2.0000 |
Open | 2.0100 |
Bid | 1.9900 x 100 |
Ask | 2.0500 x 100 |
Day's range | 1.9500 - 2.0900 |
52-week range | 1.4300 - 8.3300 |
Volume | |
Avg. volume | 3,242,438 |
Market cap | 228.131M |
Beta (5Y monthly) | 0.51 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.5300 |
Earnings date | 06 May 2024 - 10 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.43 |
Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
– In preclinical studies, CHS-1000 shows a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion –– Mechanism may enhance antitumor responses with immunotherapy –– First novel immuno-oncology product candidate discovered and developed by Coherus –– The CHS-1000 IND submission is planned for Q2 2024 – REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript March 13, 2024 Coherus BioSciences, Inc. misses on earnings expectations. Reported EPS is $-0.62 EPS, expectations were $-0.21. CHRS isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day, and thank […]